Behind five decades of growth and international recognition lies a story of vision, courage and perseverance, which has become one of the most remarkable business success stories in modern Cyprus.
In 1976, when Cyprus was still striving to recover and rebuild its economic and social foundations following the events of 1974, a young physician, Dr Andreas Pittas, chose not to pursue the certainty of a conventional professional career. Instead, he dared to pursue what many at the time considered almost impossible: the creation of an internationally competitive pharmaceutical company in Cyprus. This was the beginning of Medochemie in Limassol.
The origins of this journey can be traced back several years earlier, when Dr Pittas was studying medicine in Austria and discovering the fascinating world of pharmacology.
It was there that he realised that serving humanity could extend far beyond the practice of medicine itself. It could also be achieved through the development and production of high-quality pharmaceutical products capable of improving the lives of millions of people.
Upon his return to Cyprus, circumstances were far from favourable. Infrastructure was limited, opportunities for industrial development were scarce, and the prospect of establishing a Cypriot pharmaceutical company with an international outlook seemed unrealistic to many.
For Dr Pittas, however, his vision was never a distant aspiration. It was a profound conviction that Cyprus could build its own pharmaceutical industry and secure a respected place on the global pharmaceutical map.
The journey that followed was demanding. Securing resources, acquiring expertise, establishing manufacturing facilities and gaining the trust of international markets posed ongoing challenges.
Yet from the very beginning, one principle remained non-negotiable: quality would not be optional. It would be the foundation of the company’s existence.
Through meticulous work, unwavering determination and a steadfast commitment to the highest European standards, Medochemie gradually expanded its footprint beyond Cyprus. Early international partnerships laid the groundwork for an outward-looking strategy that would eventually become one of the country's most significant business success stories.
Fifty Years of Medochemie. Worldwide. Every Day.
Half a century later, the vision of that young doctor has evolved into the largest pharmaceutical company in Cyprus and one of the most prominent ambassadors of Cypriot pharmaceutical excellence worldwide.
Today, Medochemie operates 15 state-of-the-art manufacturing facilities, certified to the stringent EU GMP standards, nine of which are in Cyprus, one in the Netherlands and five in Vietnam.
The company also has offices in 19 countries and exports its products to 120 markets worldwide..
As Cyprus’ leading pharmaceutical exporter, Medochemie makes a significant contribution to the country’s industrial exports. Every product bearing the company’s name serves as an ambassador for Cypriot scientific expertise, innovation and manufacturing excellence across international markets.
Behind this success stand more than 2,000 employees worldwide whose knowledge, dedication and professionalism have played a decisive role in shaping the company’s modern identity.
For Medochemie, progress is measured not only by financial performance and international distinctions, but also through the creation of an environment that invests in knowledge, research, innovation and the development of its people.
A Lasting Contribution to Society
Medochemie’s contribution extends far beyond pharmaceutical manufacturing.
For five decades, the company has played an active role in the social, cultural and sporting life of Cyprus, supporting initiatives that promote education, culture, sports, scientific research and social cohesion.
Through a comprehensive Corporate Social Responsibility programme, Medochemie continuously invests in youth education, environmental protection, healthcare and the well-being of local communities, reaffirming its belief that business success acquires its greatest value when accompanied by meaningful social contribution.
The company’s contributions and achievements have repeatedly received recognition both in Cyprus and internationally.
Medochemie has been honoured fifteen times with the Industrial Export Award, twice with the Special Export Award, and has also received the Honorary Export Award. Furthermore, the prestigious European distinction Ruban d’Honneur has ranked the company among Europe’s leading export businesses.
These distinctions reflect a journey grounded in consistency, expertise and long-term strategic vision.
Fifty Years Later, Looking Towards the Future
Marking the fiftieth anniversary of the company’s founding, Medochemie’s Founder and Executive Chairman, Dr Andreas Pittas, stated:
"Fifty years later, I feel deeply grateful, not only for what we have achieved but above all for the people who have shared this journey with us. Medochemie is first and foremost its people. Those who believed in a common purpose and worked consistently, with integrity and dedication, to transform that purpose into reality."
Today, as Medochemie enters the second half-century of its history, the company continues to invest in research, new technologies, sustainable development and the further strengthening of its international presence, while remaining firmly committed to the principles that have guided it since its very first day.
Fifty years after its establishment, Medochemie continues to write its own chapter in the history of Cypriot entrepreneurship and the global pharmaceutical industry, carrying forward the principles and values that inspired Dr Andreas Pittas in 1976 and continue to shape the company’s evolution to this day.
Behind five decades of growth and international recognition lies a story of vision, courage and perseverance, which has become one of the most remarkable business success stories in modern Cyprus.
In 1976, when Cyprus was still striving to recover and rebuild its economic and social foundations following the events of 1974, a young physician, Dr Andreas Pittas, chose not to pursue the certainty of a conventional professional career. Instead, he dared to pursue what many at the time considered almost impossible: the creation of an internationally competitive pharmaceutical company in Cyprus. This was the beginning of Medochemie in Limassol.
The origins of this journey can be traced back several years earlier, when Dr Pittas was studying medicine in Austria and discovering the fascinating world of pharmacology.
It was there that he realised that serving humanity could extend far beyond the practice of medicine itself. It could also be achieved through the development and production of high-quality pharmaceutical products capable of improving the lives of millions of people.
Upon his return to Cyprus, circumstances were far from favourable. Infrastructure was limited, opportunities for industrial development were scarce, and the prospect of establishing a Cypriot pharmaceutical company with an international outlook seemed unrealistic to many.
For Dr Pittas, however, his vision was never a distant aspiration. It was a profound conviction that Cyprus could build its own pharmaceutical industry and secure a respected place on the global pharmaceutical map.
The journey that followed was demanding. Securing resources, acquiring expertise, establishing manufacturing facilities and gaining the trust of international markets posed ongoing challenges.
Yet from the very beginning, one principle remained non-negotiable: quality would not be optional. It would be the foundation of the company’s existence.
Through meticulous work, unwavering determination and a steadfast commitment to the highest European standards, Medochemie gradually expanded its footprint beyond Cyprus. Early international partnerships laid the groundwork for an outward-looking strategy that would eventually become one of the country's most significant business success stories.
Fifty Years of Medochemie. Worldwide. Every Day.
Half a century later, the vision of that young doctor has evolved into the largest pharmaceutical company in Cyprus and one of the most prominent ambassadors of Cypriot pharmaceutical excellence worldwide.
Today, Medochemie operates 15 state-of-the-art manufacturing facilities, certified to the stringent EU GMP standards, nine of which are in Cyprus, one in the Netherlands and five in Vietnam.
The company also has offices in 19 countries and exports its products to 120 markets worldwide..
As Cyprus’ leading pharmaceutical exporter, Medochemie makes a significant contribution to the country’s industrial exports. Every product bearing the company’s name serves as an ambassador for Cypriot scientific expertise, innovation and manufacturing excellence across international markets.
Behind this success stand more than 2,000 employees worldwide whose knowledge, dedication and professionalism have played a decisive role in shaping the company’s modern identity.
For Medochemie, progress is measured not only by financial performance and international distinctions, but also through the creation of an environment that invests in knowledge, research, innovation and the development of its people.
A Lasting Contribution to Society
Medochemie’s contribution extends far beyond pharmaceutical manufacturing.
For five decades, the company has played an active role in the social, cultural and sporting life of Cyprus, supporting initiatives that promote education, culture, sports, scientific research and social cohesion.
Through a comprehensive Corporate Social Responsibility programme, Medochemie continuously invests in youth education, environmental protection, healthcare and the well-being of local communities, reaffirming its belief that business success acquires its greatest value when accompanied by meaningful social contribution.
The company’s contributions and achievements have repeatedly received recognition both in Cyprus and internationally.
Medochemie has been honoured fifteen times with the Industrial Export Award, twice with the Special Export Award, and has also received the Honorary Export Award. Furthermore, the prestigious European distinction Ruban d’Honneur has ranked the company among Europe’s leading export businesses.
These distinctions reflect a journey grounded in consistency, expertise and long-term strategic vision.
Fifty Years Later, Looking Towards the Future
Marking the fiftieth anniversary of the company’s founding, Medochemie’s Founder and Executive Chairman, Dr Andreas Pittas, stated:
"Fifty years later, I feel deeply grateful, not only for what we have achieved but above all for the people who have shared this journey with us. Medochemie is first and foremost its people. Those who believed in a common purpose and worked consistently, with integrity and dedication, to transform that purpose into reality."
Today, as Medochemie enters the second half-century of its history, the company continues to invest in research, new technologies, sustainable development and the further strengthening of its international presence, while remaining firmly committed to the principles that have guided it since its very first day.
Fifty years after its establishment, Medochemie continues to write its own chapter in the history of Cypriot entrepreneurship and the global pharmaceutical industry, carrying forward the principles and values that inspired Dr Andreas Pittas in 1976 and continue to shape the company’s evolution to this day.
